Group 1: Company Overview - Tilray Brands went public in 2018 and has since faced significant challenges, with the stock losing nearly all its value despite the U.S. cannabis market exceeding $38 billion last year [1][2] - The company has evolved into a global cannabis business, initially focusing on medical cannabis and later expanding into recreational cannabis, hemp foods, and beverages [4][5] - Tilray currently sells over 40 brands of cannabis products and generated $829 million in sales last year, with projected revenue growth to $893 million this year and $943 million next year [5][6] Group 2: Financial Performance - While sales are not a concern, Tilray has struggled with profitability, reporting a free cash flow of minus $92 million and net losses nearing $250 million last year [7][8] - The U.S. cannabis market is expected to grow over 11% annually through 2030, presenting opportunities for Tilray's diverse product portfolio [6] Group 3: Challenges and Risks - The company has faced operational challenges due to varying legal statuses of cannabis across states in the U.S., leading to pricing pressures and competition from the black market [8] - Tilray's rapid expansion has resulted in a 348% increase in diluted share count since 2018, which negatively impacts revenue and profit distribution among shareholders [9][10] - Despite potential future growth, the stock is unlikely to yield significant returns for investors due to ongoing losses and share dilution [11]